EC Clinical and Medical Case Reports

The vaccines in their content have some ingredients called excipients added for a specific purpose. Excipients added in vaccines are used:

• Preservatives to prevent contamination - thimerosal.
• Adjuvants to help stimulate a stronger immune response - aluminum salts.
• Stabilizers to keep the vaccine potent during the transport and storage - sugar or gelatin.

Some excipients are residual trace amounts used during the manufacturing process and removed as the case for cell culture materials used to grow the vaccines antigens- egg protein, various culture media, and inactivating ingredients used to kill viruses or inactivate toxins such as formaldehyde. The purpose of antibiotics using in vaccines like neomycin is to prevent contamination by bacteria [1].

Keywords: Vaccine; Adjuvants; Immune Response; Excipient; Aluminum Salt

1. https://www.cdc.gov/vaccinesafety/concerns/adjuvants.html#:~:text=Adjuvants%20have%20been%20used%20safely%20in%20vaccines%20for%20decades.&text=In%20all%20cases%2C%20vaccines%20containing,FDA%20once%20they%20are%20approved
2. IOM, Thiomersal-containing vaccines, and neurodevelopmental disorders (1999).
3. Mohan T., et al. “Novel adjuvants and delivery vehicles for vaccines development: A road ahead”. Indian Journal of Medical Research 5 (2013): 779-795.
4. Sayers S., et al. “A Web-Based Vaccine Adjuvant Database and Its Application for Analysis of Vaccine Adjuvants and Their Uses in Vaccine Development”. Journal of Biomedicine and Biotechnology (2012): 831486.
5. Pifferi C., et al. “Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action”. Nature Reviews Chemistry 5 (2021): 197-215.
6. Stratmann Th. “Bordetella pertussis Bp-WCV (Bordetella pertussis whole cell vaccines)”. Vaccines 3.3 (2015): 579-596.
7. Blackwood CB., et al. “Bordetella pertussis whole cell immunization protects against Pseudomonas aeruginosa infections”. NPJ Vaccines 143 (2022).
8. Liu X., et al. “The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant”. Vaccine 6 (2008): 786-796.
9. Morein B., et al. “Immunostimulating Complexes Clinical Potential in Vaccine Development”. Clinics Immunotherapy 6 (1995): 461-475.
10. Ralving C., et al. “Adjuvants for human vaccines”. Current Opinion in Immunology 3 (2012): 310-315.
11. He P., et al. “Advances in aluminum hydroxide-based adjuvant research and its mechanism”. Human Vaccines and Immunotherapeutic 2 (2015): 477-488.
12. Mbow ML., et al. “New adjuvants for human vaccines”. Current Opinion in Immunology 3 (2010): 411-415.
13. Pasquale AD., et al. “Vaccine Adjuvants: from 1920 to 2015 and Beyond”. Vaccines2 (2015): 320-343.
14. https://www.cdc.gov/vaccinesafety/concerns/adjuvants.html
15. Ishaq MU., et al. “Role of cytosine-phosphate-guanosine-Oligodeoxynucleotides (CpG ODNs) as adjuvant in poultry vaccines”. Published online by Cambridge University Press (2018).
16. Mani R., et al. “Adjuvant Potential of Poly-α-L-Glutamine from the Cell Wall of Mycobacterium tuberculosis”. Infection and Immunity 10 (2018): e00537-18.
17. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-adjuvants-vaccines_en.pdf
18. Petrovsky N. “Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs”. Drug Safety 11 (2015): 1059-1074.
19. Facciolà A., et al. “An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives”. Vaccines 5 (2022): 819.